Intranasal Oxytocin and Social Cognition, Implicit Preferences and Craving in Alcohol Drinkers
Completed · Phase 4 · Has a placebo group
Conditions studied: AOD Use, Abuse, and Dependence
In brief
This is a randomized, placebo controlled, double blind crossover study of the effects of intranasal oxytocin on social cognition, implicit preferences and craving in moderate to heavy social alcohol drinkers.
Key facts
- Study ID
- NCT01829516
- Run by
- University of California, San Francisco
- People needed
- 32
- Starts
- 2013-05-01
- Expected to finish
- 2014-11-01
- Last updated by the study team
- 2016-07-27
Who can join
Age: 18 and older, up to 50. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- Subject is a volunteer between 18 and 50 years of age.
- If female, subject is non-lactating, not pregnant, and using a reliable contraception method (i.e. abstinence, intrauterine device [IUD], hormonal birth control, or barrier method).
- Subject is able to read and speak English.
- Subject is able and willing to provide written informed consent.
- Subject is able to understand and follow the instructions of the investigator and understand all screening questionnaires.
- Subject is in good health.
You may not qualify if…
- Positive urine drug screen (except marijuana).
- Using cocaine, stimulants (other than nicotine and caffeine), amphetamines, hallucinogens, ecstasy, opiates, sedatives, pain pills, sleeping pills, or other psychoactive drugs within 2 weeks of the start of the study (except marijuana) OR more than 10 times in the last year (except marijuana).
- Marijuana use more than 3 times/week.
- Has a current dependence on, or addiction to any psychoactive drug (except nicotine or caffeine) including alcohol OR a recent history of substance abuse other than alcohol, tobacco or marijuana.
- Clinically significant medical or psychiatric illness requiring treatment as determined by screening blood tests, medical history, and/or physical exam performed or reviewed by the study physician.
- BAC level > 0.05% at the beginning of screening visit (within margin of error of detection).
- Has a neurological dysfunction or psychiatric disorder (confirm with study physician).
- Has a history of brain trauma (confirm with study physician).
- Has an allergy or intolerance to oxytocin.
- Subject has received an investigational drug within 30 days of Screening Visit.
- Subject is considered unsuitable for the study in the opinion of the investigator, nurse practitioner, or study physician for any other reason.
Where it is running
- Ernest Gallo Clinic and Research Center — Emeryville, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.